[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596671":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":24,"studyPopulation":17,"armGroups":17,"interventions":25,"overallOfficials":17,"centralContacts":29,"locations":35,"responsibleParty":55,"collaborators":60,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":17,"enrollmentInfo":72,"targetDuration":17,"studyType":75,"phases":76,"briefSummary":24,"conditions":77,"keywords":17,"overallStatus":38,"whyStopped":17,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Abramson Cancer Center at Penn Medicine","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"Rate of adherence to BCG therapy at 3 months after study initiation","The primary outcome will be the rate of adherence to AUA guidelines for BCG therapy as measured by successful treatments of BCG compared to expected treatments. For each participant, adherence will be calculated both as the percentage of adherent doses, evaluable for study participants","3 months after study initiation",[14],{"measure":15,"description":16,"timeFrame":12},"• Self efficacy as measured by the validated General Self efficacy scale, a 10-item scale, measured at 3 months after study initiation","The secondary outcomes will include self-efficacy and symptom management.",null,{"allocation":19,"interventionModel":20,"interventionModelDescription":17,"primaryPurpose":21,"observationalModel":17,"timePerspective":17,"maskingInfo":22},"NA","SINGLE_GROUP","TREATMENT",{"masking":23,"maskingDescription":17,"whoMasked":17},"NONE","The proposed project will have two separate cohorts. The first will be to perform a more in-depth qualitative assessment of the barriers and facilitators for treatment compliance for non-muscle invasive bladder cancer. The second arm will be to create and test a BCG at home program. Participants in the second cohort will be enrolled in a conversational agent to measure patient symptoms and quality of life and improve self-efficacy.",[26],{"type":6,"name":27,"description":28,"armGroupLabels":17,"otherNames":17},"BCG delivery at home","The BCG at home project will be a single-arm prospective pilot, to evaluate the feasibility, scalability and effectiveness of home treatment, and utilize the BB-Bot (chatbot) for PRO and adverse event measurement.",[30],{"name":31,"role":32,"phone":33,"phoneExt":17,"email":34},"Daniel Lee, PI, MD","CONTACT","215-615-3780","daniel.lee4@pennmedicine.upenn.edu",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Abramson Cancer Center","RECRUITING","Philadelphia","Pennsylvania","19104","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-75.16362,39.95238,{"lat":48,"lon":47},[51],{"name":52,"role":32,"phone":53,"phoneExt":17,"email":54},"Daniel J Lee, MD, MS","215-662-2891","Daniel.Lee4@pennmedicine.upenn.edu",{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":59,"oldNameTitle":17,"oldOrganization":17},"PRINCIPAL_INVESTIGATOR","Daniel Lee, MD, MS","Principal Investigator","University of Pennsylvania",[61],{"name":62,"class":6},"Blue Cross Blue Shield","100596671","intravesical-treatment-of-bladder-cancer-at-home-multi-modal-treatment-support-100596671",false,"NCT07048496","Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support","BCG at Home","Inclusion Criteria:\n\nInclusion criteria for patients in Cohort 1\n\n* Age 18 years or older;\n* completed intravesical treatment for non-muscle invasive bladder cancer within the past year Cohort 1 inclusion criteria for key stakeholders\n* Age 18 years or older;\n* experience with the delivery of BCG delivery for more than 2 years\n\nCohort 2 inclusion criteria\n\n* Age 18 years or older;\n* diagnosed with non-muscle invasive bladder cancer and prescribed BCG for initial therapy\n\nExclusion Criteria:\n\nCohort 1 exclusion criteria\n\n• inability to provide informed consent\n\nCohort 2 exclusion criteria\n\n* inability to provide informed consent\n* inability to undergo catheterization (i.e. - history of urethral stricture)\n* inability to receive BCG therapy (i.e. - previous reaction with BCG)\n* no access to mobile phone\n* inability to respond to written conversations in English","ALL","18 Years",{"count":73,"type":74},50,"ESTIMATED","INTERVENTIONAL",[19],[78],"Bladder Cancer","2026-10-01",{"date":81,"type":82},"2026-10-05","ACTUAL",{"date":84,"type":82},"2025-07-05",{"date":86,"type":74},"2027-04-05",{"name":5,"class":6},1]